hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06283524, orgStudyIdInfo id: ETNA-TrainMS, briefTitle: Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2025-10-18, completionDateStruct date: 2026-03-18, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Innodem Neurosciences, class: INDUSTRY, descriptionModule briefSummary: The overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in MS patients to train machine learning algorithms that will support the development and performance assessment of a sensitive and non-invasive eye-tracking software application. The training of our machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of MS disease severity and cognitive status., conditionsModule conditions: Multiple Sclerosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Eye-Tracking, outcomesModule primaryOutcomes measure: Predictive power of eye-movement biomarkers (EMBs) for MS severity in relationship to Expanded Disability Status Scale (EDSS), secondaryOutcomes measure: Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Symbol Digit Modalities Test (SDMT) as part of the Brief International Cognitive Assessment for MS (BICAMS)., secondaryOutcomes measure: Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Rey Auditory Verbal Learning Test (RAVLT) as part of the Brief International Cognitive Assessment for MS (BICAMS)., secondaryOutcomes measure: Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Brief Visuospatial Memory Test-Revised (BVMT-R) as part of the Brief International Cognitive Assessment for MS (BICAMS)., secondaryOutcomes measure: Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the Timed 25-foot walk as part of the Multiple sclerosis functional composite (MSFC)., secondaryOutcomes measure: Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the 9-Hole Peg Test (9-HPT) as part of the Multiple sclerosis functional composite (MSFC)., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Genge Partners, Inc., city: Montréal, state: Quebec, zip: H4A 3T4, country: Canada, contacts name: Yousri Benchaar, role: CONTACT, phone: 514-906-3876, phoneExt: 6026, email: YBenchaar@gengepartners.com, contacts name: Alexander Saveriano, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06283511, orgStudyIdInfo id: IJB-RESTART, briefTitle: Evaluation of the RESTART Survival Programme, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Jules Bordet Institute, class: OTHER, descriptionModule briefSummary: The RESTART survivorship programme has been implemented in the care pathway for patients with localised breast cancer since 2022. In this project, investigators are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme., conditionsModule conditions: Invasive Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: educational workshops, outcomesModule primaryOutcomes measure: Assessment of satisfaction with participation in the Restart programme and its various components via Likert scale and open questions., secondaryOutcomes measure: assessment of quality of life, secondaryOutcomes measure: assessemnt of health literacy via HLQ questionnaire, secondaryOutcomes measure: assessment of professional status, secondaryOutcomes measure: assessment of level of physical activity, secondaryOutcomes measure: assessment of emotionnal distress, secondaryOutcomes measure: assessment of the intensity of residual fatigue, secondaryOutcomes measure: assessment of sleep quality, secondaryOutcomes measure: Measuring the rate of participation in the programme, secondaryOutcomes measure: assessment of quality of life, secondaryOutcomes measure: assessment of emotionnal distress, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06283472, orgStudyIdInfo id: 1805574553; Aims 14-16, secondaryIdInfos id: 2P60AA007611-403343, type: OTHER_GRANT, domain: National Institute on Alcohol Abuse and Alcoholism, secondaryIdInfos id: 2P60AA007611, type: NIH, link: https://reporter.nih.gov/quickSearch/2P60AA007611, briefTitle: Enhancing Prospective Thinking in Early Recovery (BEAM), acronym: BEAM, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-12-01, completionDateStruct date: 2027-02-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Indiana University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test the prosocial effects of personally-relevant, high-intensity episodic future-thinking (EFT) cues in alcohol use disorder persons and related brain mechanisms. The main question\[s\] this trial aims to answer are:* Will high-intensity EFT cues will produce greater delayed reward preference than low-intensity cues?* Will high-intensity EFT cues effect greater treatment-seeking interest?* Will high-intensity EFT cues elicit greater response in regions for prospective thinking during delay discounting (vs. low-intensity)* Will nucleus accumbens-precuneus resting connectivity correlate with behavioral SS?* Will the novel behavioral SS decision-making task activate the nucleus accumbens?Researchers will compare the experimental (high-intensity group) and control (low-intensity) groups to see if there are differences in the results for the questions outlined above., conditionsModule conditions: Alcohol Use Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: Eligible participants will be randomly assigned to either the high-intensity (experimental) or low-intensity (control) groups., whoMasked: PARTICIPANT, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: High-Intensity Cue, interventions name: Low-Intensity Cue, outcomesModule primaryOutcomes measure: Increase Prospective Thinking, primaryOutcomes measure: Delayed Rewards, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06283459, orgStudyIdInfo id: 301-23-101, briefTitle: Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-09-30, completionDateStruct date: 2025-09-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Imunon, class: INDUSTRY, descriptionModule briefSummary: This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study Day 365)., conditionsModule conditions: SARS CoV 2 Infection, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: IMNN-101, outcomesModule primaryOutcomes measure: Number of participants with local and systemic reactogenicity adverse events and all adverse events, primaryOutcomes measure: Number of participants with geometric mean titer (GMT) of the serum neutralizing antibody (Nab) against the Omicron XBB.1.5 strain., secondaryOutcomes measure: Number of participants with GMT of serum spike binding IgG antibodies, secondaryOutcomes measure: Number of participants with a magnitude and phenotype of cytokine producing S protein-specific T cells, as measured by flow cytometry and/or ELISpot., secondaryOutcomes measure: Number of participants with seroresponse rate (SRR)., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beth Israel Deaconess Medical Center, city: Boston, state: Massachusetts, zip: 02215, country: United States, contacts name: Elizabeth Oginni, role: CONTACT, email: ooginni@bidmc.harvard.edu, contacts name: Ai-Ris Y Collier, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, locations facility: DM Clinical Research, city: Philadelphia, state: Pennsylvania, zip: 19107, country: United States, contacts name: Kyle Bramble, role: CONTACT, email: kyle.bramble@dmclinical.com, contacts name: Kem Yenal, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06283446, orgStudyIdInfo id: 1805574553; Aims 11-13, secondaryIdInfos id: 1R21AA029760-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1R21AA029760-01, briefTitle: Enhancing Prospective Thinking in Early Recovery, acronym: NERF, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-20, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Indiana University, class: OTHER, collaborators name: National Institute on Alcohol Abuse and Alcoholism (NIAAA), descriptionModule briefSummary: The goal of this clinical trial is to test the prosocial effects of personally-relevant, high-intensity episodic future-thinking (EFT) cues in alcohol use disorder persons and related brain mechanisms. The main question\[s\] this trial aims to answer are:Will high-intensity EFT cues will produce greater delayed reward preference than low-intensity cues? Will high-intensity EFT cues effect greater treatment-seeking interest? Will high-intensity EFT cues elicit greater response in regions for prospective thinking during delay discounting (vs. low-intensity) Will nucleus accumbens-precuneus resting connectivity correlate with behavioral SS? Will the novel behavioral SS decision-making task activate the nucleus accumbens? Researchers will compare the experimental (high-intensity group) and control (low-intensity) groups to see if there are differences in the results for the questions outlined above., conditionsModule conditions: Alcohol Use Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: Eligible participants will be randomly assigned to either the high-intensity (experimental) or low-intensity (control) groups., whoMasked: PARTICIPANT, enrollmentInfo count: 98, type: ESTIMATED, armsInterventionsModule interventions name: High-Intensity Cue, interventions name: Low-Intensity Cue, outcomesModule primaryOutcomes measure: Increase Prospective Thinking, primaryOutcomes measure: Delayed Rewards, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Indiana University School of Medicine - Goodman Hall, status: RECRUITING, city: Indianapolis, state: Indiana, zip: 46202, country: United States, contacts name: Sarah Turo, BA, role: CONTACT, phone: 317-963-7220, email: sturo@iu.edu, contacts name: Colton Lind, BS, role: CONTACT, phone: 317-963-2554, email: cmlind@iu.edu, contacts name: Brandon G Oberlin, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.76838, lon: -86.15804, hasResults: False
protocolSection identificationModule nctId: NCT06283420, orgStudyIdInfo id: CarDia_WP5_P1_IRB:25059/23, briefTitle: Metabolic Response to Iniciation of Heart Failure Therapy, acronym: GliF, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2025-12-20, completionDateStruct date: 2026-12-20, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Vojtech Melenovsky, MD, PhD, class: OTHER_GOV, descriptionModule briefSummary: This protocol is part of the CarDia project - National Institute for Metabolic and Cardiovascular Disease Research (EXCELES Program, ID: LX22NPO5104), funded by the European Union - Next Generation EU. The protocol is part of Work Package 5 (WP5): metabolic disorders in heart failure.The goal of this observational protocol is to monitor the biochemical and metabolomic response to the initiation of therapy for heart failure with standard drugs (SGLT2i, sGC stimulators, ARNI) and whether this early response (within first 3 months) predicts the further course of the disease.The protocol will examine how parameters reflecting neurohumoral activation, response to hypoxia, systemic metabolism of energy substrates, parameters of iron metabolism, HIF1A activation in peripheral blood behave over time after starting standard heart failure terapiy (baseline, 1 day, 1 week, 1 month, 3 month). This project can provide valuable information on how to identify people who respond more poorly to the treatment being introduced and are more at risk of an adverse course of the disease. Patients will be compared to patients who have no change of therapy over early observation period (3 mo), who will serve as controls. This is observational study, so decision to inicialize therapy will be based on medical indication.Patients with heart failure treated at the IKEM Cardiocenter will have blood drawn at several defined intervals before and after the start of clinically indicated treatment. Some patients will also undergo genetic DNA testing to determine the variability of genes regulating the metabolic neurohumoral response to heart failure. Patients will be contacted at intervals of 1 and 2 years and the incidence of clinical events will be monitored. The study is observational in nature and inclusion in the study does not affect the course of care provided or the choice of pharmacotherapy., conditionsModule conditions: Heart Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: hematocrit, secondaryOutcomes measure: HIF response, secondaryOutcomes measure: hepcidin, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institute for Clinical end Experimental Medicine - IKEM, city: Prague, country: Czechia, geoPoint lat: 50.08804, lon: 14.42076, hasResults: False
protocolSection identificationModule nctId: NCT06283407, orgStudyIdInfo id: ICF, briefTitle: ICF-based Comparison on Musculoskeletal Health in Poland and Spain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2024-06-03, completionDateStruct date: 2024-11-04, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University of Rzeszow, class: OTHER, collaborators name: Sanidad de Castilla y León, descriptionModule briefSummary: Musculoskeletal conditions are a major cause of disability worldwide. These conditions are often associated with chronicity, which is a challenge for healthcare systems to address. Health care must be person-centred and take into account the individual perspective from which the disease is experienced. The lived experience of health conditions depends to a large extent on contextual factors. Comparison between different contexts helps to identify which aspects are most relevant in the experience of the disease. The International Classification of Functioning, Disability and Health (ICF) provides a unified language that allows such comparisons to be made. The aim of this study is to identify differences in musculoskeletal health between the Polish and Spanish populations using the ICF as a frame of reference., conditionsModule conditions: Musculoskeletal Diseases or Conditions, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 800, type: ESTIMATED, armsInterventionsModule interventions name: ICF-based cross-country comparative analysis, outcomesModule primaryOutcomes measure: Brief International Classification of Functioning, Disability and Health (ICF) core set for post-acute musculoskeletal conditions, secondaryOutcomes measure: Sociodemographic data of the sample (nationality, age, sex, education level, work status, number of comorbidities), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Rzeszow, city: Rzeszów, zip: 35-959, country: Poland, contacts name: Agnieszka Wiśniowska-Szurlej, role: CONTACT, geoPoint lat: 50.04132, lon: 21.99901, hasResults: False
protocolSection identificationModule nctId: NCT06283394, orgStudyIdInfo id: 854803, briefTitle: AHA (American Heart Association) Food is Medicine Test of Choice Architecture and Salience of Incentives, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2025-05-15, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: University of Pennsylvania, class: OTHER, descriptionModule briefSummary: The goal of this interventional study is to test ways to improve the effectiveness of a healthy foods prescription program in increasing the purchase of healthy foods for patients who have both obesity (BMI \> 30) and diabetes (last A1C\>8 in the last 90 days). The main questions it aims to answer are:Aim 1: Examine feasibility and engagement among participants by assessing percent enrollment among those identified as eligible, rates of Instacart platform use, amount of the subsidy used each week, and amounts of healthy foods ordered.Aim 2: Examine strategies to optimize the user experience of trial participation, including communication strategies and on-boarding, to increase uptake and engagement in this and subsequent studies.Usual Care (Control): Participants in the usual care arm will not receive weekly subsidies on Instacart, and they will not receive any modifications to the virtual storefront on Instacart. They will have access to the standard Instacart platform and Instacart + memberships with $5 per week to cover service and delivery fees and delivery tips for 3 months.Intervention Arms: The four treatment groups will also each receive a $160 subsidy per month for 3 months to be used on produce (fruits and vegetables)., conditionsModule conditions: Obesity, conditions: Diabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: Storefront Choice Architecture, interventions name: Fresh Funds, interventions name: Loss Framing, outcomesModule primaryOutcomes measure: The primary outcome will be the percentage of food purchasing expenditures spent on eligible healthy foods., secondaryOutcomes measure: Percentage of the $160 subsidy used each month in the intervention arms., secondaryOutcomes measure: Change in hemoglobin A1c, secondaryOutcomes measure: Qualitative results, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06283381, orgStudyIdInfo id: 4264, briefTitle: The ESG Integrity Study: Effect of Proton Pump Inhibitors on the Structural Integrity of Endoscopic Sleeve Gastroplasty, acronym: ESGIS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2025-01-31, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: The study is a single center randomized, open-label, phase IV clinical trial. Obese patients who have indication to Endoscopic sleeve gastroplasty (ESG) for clinical reasons are included and ESG is performed as per clinical practice. After randomization, the patients are divided in two arms:* Arm A: patients will stop proton pump inhibitors (PPI) 24h after the procedure.* Arm B: patients will assume oral Esomeprazole 40 mg twice a day for 4 weeks and 40 mg once a day for 4 weeks (total 8 weeks of PPIs after ESG- standard current treatment).The primary aim of the study is to evaluate the effect of PPI on the structural integrity of the ESG, conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Esomeprazole, outcomesModule primaryOutcomes measure: The structural integrity of the sutures after Endoscopic sleeve gastroplasty (ESG), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione Policlinico Universitario A. Gemelli IRCCS, status: RECRUITING, city: Roma, zip: 00168, country: Italy, contacts name: IVO BOSKOSKI, role: CONTACT, phone: +390630155701, email: ivo.boskoski@policlinicogemelli.it, contacts name: IVO BOSKOSKI, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False